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Since the beginnings of 
biotechnology, more or less formally 
recognized scientific discipline, fungi – 
the organisms used in biosynthesis and 
biotransformations of various types of 
substances have been in the focus  
of interest.  However, for a long time 
researchers concentrated mainly  
on species informally classified as lower 
fungi. In pharmaceutical biotechnology, 
for example, filamentous fungi of the 
genera Penicillium, Cephalosporium, 
Aspergillus or Fusidium are employed in 
the production of antibiotics, vitamins, 
enzymes and organic acids (citric acid, 
itaconic acid, fusaric acid and gluconic 
acid). In recombinant DNA techniques 
(e.g. in insulin production), 
Saccharomyces cerevisiae Meyen ex 
E.C. Hansen yeast is used as a recipient 
of DNA. Among higher fungi, a 
systematically heterogeneous group  
of fungi belonging to Ascomycotina, 
Basidiomycotina, and former 
Deuteromycotina, characterized by the 
ability to form fruiting bodies, for a long 
time the only process that could be 
classified as biotech (a process which 
comprises cultivating of the inoculum, 
preparation and sterilization of the 
substrate, inoculation and culturing the 
strain under defined conditions) was 
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cultivation of edible mushrooms under 
semicontrolled conditions. 
Research conducted by Gregory can 
be considered as the first attempt to use 
the submerged cultures of higher fungi in 
classical biotechnological processes. In 
1966, Gregory published the results of 
the search for new antitumor substances 
in the fruiting bodies of more than  
200 species of fungi belonging  
to Basidiomycetes class. He searched for 
pharmacologically active substances also 
in approximately 7 000 post-culture 
liquid media used for submerged 
cultivation of different species of higher 
fungi. The isolated substances (mainly 
polysaccharides) demonstrated an 
inhibitory effect on tumor cells, including 
cancers such as Kaposi S-180, 
adenocarcinoma 755 and leukemia L-
1210. Recently submerged culture of 
mycelium, conducted in bioreactors of 
different structures, in liquid or solid 
media has been the most typical 
biotechnological process with the use of 
higher fungi. Development and 
optimization of such processes focus 
mainly on: 
- isolation of biologically active 
metabolites, often pharmacologically 
active substances (drugs, vitamins), 
synthesized by fungal cells (from 
mycelium or a culture medium); 
- production of biomass rich in 
nutrients to be used as food, functional 
foods and food supplements; 
- production of biomass rich in 
biologically active substances (mainly 
antioxidants) to be used in cosmetology; 
- isolation of enzymes (mainly 
peroxidases), synthesized by cultured 
fungi, which are subsequently used in the 
processes of biotransformation and 
bioremediation or in chemical syntheses; 
- the use of cultured mycelium  




The advantages and disadvantages of biotechnological methods of mushroom 
cultivation 
Biotechnological methods of 
cultivation of higher fungi in many 
respects surpass the methods used for 
cropping: 
- the major advantage consists in 
short cultivation time in bioreactors, 
especially in liquid media. In comparison 
with the duration of mushroom cropping, 
this significantly reduces the time 
necessary to obtain a comparable 
biomass; 
- the mycelial cultures in bioreactors 
are carried out under repeatable 
conditions, resulting in a stable 
composition of the biomass grown. This 
facilitates the standardization of the 
preparations derived from fungi, for 
example for pharmaceutical use; 
- optimization of the composition of 
the culture media and the physico-
chemical factors of the culture allows to 
a regulate metabolism of the cultivated 
mycelia, thus significantly increasing in 
efficiency of the biosynthesis of 
biologically active compounds (e.g. 
secondary metabolites); 
- technology of the biotechnological 
processes ensures monitoring and 
maintaining of biochemical and genetic 
identity of mycelia grown in a fermenter. 
There are also serious difficulties in 
the use of modern biotechnological 
methods in cultures of higher fungi: 
- not all strains of the higher fungi are 
able to grow efficiently as mycelial 
cultures in bioreactors; 
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- in the case of certain species of 
fungi there are significant differences in 
the chemical composition of fruiting 
bodies and mycelium cultivated 
biotechnologically. These differences are 
not always advantageous when mycelial 
cultures are used to prepare biologically 
active preparations; 
- the metabolic pathways of 
biosynthesis of biologically active 
substances by fungi are still not well 
characterized and described, as compared 
to plants or filamentous fungi. This 
makes it difficult to design and to 
optimize a biotechnological process, for 
example by the selection of precursors of 
biosynthesis or strain growth promoters; 
- it is difficult to use genetic 
engineering methods in higher fungi, due 
to the lack of complete knowledge on the 
genes encoding the biosynthesis 
pathways for the whole or part thereof.
 
Higher fungi species used in biotechnological processes 
Biotechnological processes with the 
use of saprotrophic mushrooms 
belonging to white rot fungi are among 
the most studied, well-developed and in 
practice easiest to conduct. In particular 
the white rot fungi regarding as 
medicinal mushrooms are often used in 
biotechnological processes.  
Higher fungi of the class 
Basidiomycetes represent about 30% of 
all fungal species (Kirk et al. 2008). 
About 700 of them are able to synthesize 
metabolites with pharmacological, very 
often (651 species) anticancer and 
immunostimulating activity. This group 
of mushrooms is reffered to as  
‘medicinal mushrooms’ (Wasser and 
Weiss 1999). Among the most studied 
medicinal mushrooms there are about 30 
species of fungi. They are able to 
synthesize compounds of diversified 
pharmacological activity: antitumor, 
immunomodulatory, antiviral (including 
anti-HIV), antibacterial, anti-
inflammatory, antifungal, anti-diabetic, 
hepatoprotective, nerve tonic, 
hypotensive, as well as the activity 
lowering blood levels of cholesterol and 
triglycerides (Sumiyoshi et al. 2010, 
Elisashvili 2012, Lo et al. 2012, Patel & 
Goyal 2012, Cheng et al. 2013, Croccia 
et al. 2013, Kylyc et al. 2013, Lei et al. 
2013, Lin et al. 2013, Mendez-Espinoza 
et al. 2013, Mizuno & Nishitani 2013, 
Park et al. 2002, Rony et al. 2013, 
Rouhana-Toubi et al. 2013, Wu X. et al. 
2013, Yamanaka et al. 2013, Yu et al. 
2013, Zhu et al. 2013, Hsu et al. 2014). 
Overview of the most interesting 
species of medicinal mushrooms and 
their pharmacological activity is 
presented in Table 1, showing a modified 
version of the data published by Wasser 
and Weiss (1999). The most valuable 
species, from the pharmacological point 
of view as well as their use in production 
of pharmaceutical formulations (drugs, 
food supplements, functional foods), 
include Lentinula edodes, Ganoderma 
lucidum, Trametes versicolor, 
Schizophyllum commune, Hericium 
erinaceus, and Grifola frondosa. There 
are four formulations (registered in 
several countries as drugs) used in cancer 
therapy, isolated from the fruiting bodies 
or mycelia of basidiomycetes (Mizuno 
1999):  
- Lentinan – a polysaccharide fraction 
isolated from Lentinula edodes,  
- Schizophyllan (SPG, sonifilan, 
sizofilan) – a polysaccharide fraction 
isolated from Schizophyllum commune, 
- Grifolan – a polysaccharide fraction 
isolated from Grifola frondosa, 
- Krestin – a polysaccharide PSK and 
PSP-complex polysaccharide-protein 
isolated from Trametes versicolor.
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Table 1. Cross index of the most interesting species of medicinal mushrooms and their pharmacological 
activity (Wasser & Weiss 1999, modified). x = commercially developed mushroom product (drug or dietary 
supplement); + = non commercially developed mushroom product; * = the most widely used species of fungi 
and their most important activities from pharmacological point of view are in bold. 
 PHARMACOLOGICAL ACTIVITY 
1 2 3 4 5 6 7 8 9 10 1
1 








































































































































































  +   + x x       x 
Tremella 
fuciformis Berk. 
 + +     + + +  +   x 
Schizophyllum 
commune Fr. 




  x       x  x   x 
Grifola frondosa 
(Dicks.) Gray 




   +  +      +    
Fomitopsis 
pinicola (Sw.) P. 
Karst. 












  x       x   x  x 
Inonotus obliquus 
(Ach. ex Pers.) 
Pilát 
 x x       x  x    
Lenzites betulina 
(L.) Fr. 












  + + +     +      
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x               
Armillariella 
mellea (Vahl) P. 
Karst. 









 x              
Agaricus blazei 
Murrill 












+  +     +        
 
Methods for the submerged 
cultivation in the mycelial cultures of 
practically all of above mentioned 
mushroom species have been developed 
and published (Kim et al. 2002, Chang et 
al. 2006, Cui et al. 2006, Liu & Wang 
2007, Malinowska et al. 2009, Kim et al. 
2010, Turło et al. 2010c, Elisashvili 
2012, Lo et al. 2012, Patel & Goyal 
2012, Atli et al. 2013, Habijanic et al. 
2013, Hsu et al. 2014, Khan et al. 2013,  
 
Liang et al. 2013, Jeong et al. 2013, Yue 
et al. 2013, Wu F.C et al. 2013).  
Production of the mushroom-derived 
products is a rapidly expanding industry. 
As mentioned above, the mushroom-
derived immunomodulating and 
anticancer compounds are used in 
clinical applications as adjuvant to 
standard chemotherapy (Lindequist et al. 
2005, Arora et al. 2013, Durgo et al. 
2013). There are also several types of 
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dietary supplements derived from the 
medicinal mushrooms: dried and 
pulverized fruiting bodies, hot water and 
alcohol extracts of fruiting bodies, 
biomass or extracts of mycelia, or broth 
harvested from submerged liquid 
cultures. Commercial preparations are 
available as tablets, capsules or elixirs in 
most Asian countries and their presence 
in the USA, New Zealand, Australia, and 
Europe increases. In 1999 worldwide 
sales of mushroom dietary supplement 
products (nutriceuticals) had the value of 
$5-6 billion US (Chang and Buswell 
1999, Wong and Cheung 2008) and have 
been increasing by between 10-20% 
annually. The current market value has 
been estimated to exceed of $14 billion 
per year (U.S. Food and Drug 
Administration). According to Wong and 
Cheung (2008), nearly 80% of medicinal 
mushroom products are derived from 
fruit bodies (e.g. Lentinan from L. 
edodes, Grifon D from G. frondosa, and 
practically all preparations from 
Ganoderma lucidum), 15% are based on 
extracts from mycelium (e.g. Krestin and 
PSP from T. versicolor, LEM and LAP 
from L. edodes), the smallest part from a 
culture medium (e. g. Sonifilan from S. 
commune, PSPC from Tricholoma 
lobayense R. Heim). However, due to 
increasing demands for quality and 
standardization of products, the share of 
biotech-derived preparations in the 
market is constantly growing.  
The white rot fungi, including species 
unformally classified as higher fungi, are 
unique in their ability to completely 
degrade lignin in biotechnological 
processes (Tien and Kirk 1988). This 
process  is mediated by fungal redox 
enzymes: lignin peroxidases (LiP), Mn-
dependent peroxidases (MnP), versatile 
peroxidases (VP), other peroxidases, 
laccases, and tyrosinases (Bucke 1998, 
Mester et al. 1997, Singh 2006, Turło & 
Turło 2013). The fungal redox enzymes 
are non-specific for substrate and non-
stereoselective, therefore able to 
transform a broad spectrum of organic 
pollutants, such as polycyclic aromatic 
hydrocarbons, pesticides, dyes, plastics 
and explosives (Bumpus et al. 1985, Aust 
& Benson 1993, Field et al. 1992, Wong 
2009, Hammel & Cullen 2008, Shukla & 
Varma 2011). The lignolytic enzymes of 
the white rot fungi are active 
extracellulary, therefore these organisms 
are better candidates for the 
biotransformation of apolar pollutants 
than non-lignolytic microorganisms 
(Field et al. 1992). The fungal redox 
enzymes are produced under nutrient-
limiting conditions (Moreira et al. 2000, 
Couto et al. 2002). Their synthesis is not 
induced by the presence of pollutants 
(Barr & Aust 1994). All the above 
mentioned features make the white rot 
fungi applicable in bioremediation 
processes, implemented in situ or ex situ. 
Ex situ processes are performed as 
typical submerged cultures carried out in 
bioreactors. Submerged cultures of the 
white rot fungi are also used for 
biosynthesis of lygnolytic enzymes that, 
after the isolation from the post-
cultivation medium, are used, native or 
immobilized, in the biotransformation of 
xenobiotics. The list of fungal strains 
used in mycoremediation (a form of 
bioremediation that uses conditioned 
native fungi or fungal mycelium to 
remove and degrade contaminants; Singh 
2006) is very long and includes also the 
white rot fungi described above as 
medicinal mushrooms. Besides widely 
examined Phanerochaete chrysosporium 
Burds. (Kubatova et al. 1998, Takada et 
al. 1996), several other white rot fungi, 
e.g. Pleurotus ostreatus (Kubatova et al. 
1998, Beaudette et al. 2000), Coriolopsis 
polyzona (Pers.) Ryvarden (Vyas et al 
1994, Novotny et al. 1997), Trametes 
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(Coriolus) versicolor (Berry et al. 1993, 
Sasek et al. 1993, Cloete & Celliers 
1999, Beaudette et al. 2000, Koller et al. 
2000, Ruiz-Aguilar et al. 2002), 
Bjerkandera adusta (Willd.) P. Karst. 
(Beaudette et al. 2000), Trametes trogii 
Berk. (Levin et al. 2003), Phlebia 
lindtneri (Pilát) Parmasto (Singh 2006, 
Kamei & Kondo 2005), Trametes 
(Coriolus) hirsuta (Wulfen) Lloyd 
(Orihara et al. 2005), Phanerochaete 
sordida (P. Karst.) J. Erikss. & Ryvarden 
(Valli et al. 1992), Pleurotus 
pulmonarius (Fr.) Quél. (Masaphy et al. 
1996), Hypholoma fasciculare (Huds.) P. 
Kumm., Stereum hirsutum (Willd.) Pers. 
(Bending et al. 2002), are also known to 
metabolize organopollutants. Numerous 
processes using higher fungi for 
degradation of environmental pollutants 
have been patented; however, a 
significant part of them is still at the 
stage of preliminary experiments. Only a 
few companies (e.g. Earth Fax 
Development Corporation in United 
States, Gebruder Huber Bodenrecycling 
in Germany) employ fungal cultures for 
soil bioremediation, but a broader use 
probably will take place in the future.  
Submerged cultures of mycorrhizal 
fungi raise more problems, especially 
when optimizing the culture media, but 
are also possible to conduct. In the 
experiments performed in our laboratory 
we have successfully conducted the 
bioreactor cultures of such mushroom 
species as Lactarius deliciosus (L.) Gray, 
Boletus edulis Bull., Tuber aestivum 
Vittad., Tuber brumale Vittad. The 
purpose of these experiments was to 
obtain biomass of preferred nutritional 
composition, including typical flavor and 
aroma volatiles of fungi. 
 
The cultivation methods for the production of fungal biomass, enzymes and 
bioactive metabolites 
In fungal biotechnology there are 
used several different techniques and 
substrates. In general regarding the 
substrates used, the methods are divided 
into: 
- solid-state fermentation (SSF) 
defined as a process occurring in the 
absence or near absence of free liquid, 
employing an inert or natural substrate as 
a solid support. The method is used for 
bioconversion of plant waste materials 
into foods (mushroom fruit bodies), 
fodder, enzymes, secondary metabolites 
(e.g. drugs, food supplements). The 
advantages of SSF: small energy 
consumption, cheap substrates (natural 
lignocellulosic materials, food-industry 
residues), concentrated media resulting in 
smaller bioreactor dimensions (Pandey et 
al. 2000, Couto & Toca-Herrera 2007, 
Petre & Teodorescu 2012). The 
disadvantages: problems with isolation 
and purification of the products, difficult 
or impossible control of the process 
parameters (pH, temperature, aeration), 
inhomogeneous culture conditions (e.g. 
difficulties in oxygen transport, 
agitation); 
- submerged liquid cultures working 
as homogenous systems under the full 
process control (pH, agitation, 
concentration of medium components, 
oxygenation, medium density). This 
method permits fully standardized 
production of the fungal biomass with 
high nutritional value or biosynthesis of 
mushroom metabolites with predictable 
composition. The downstream processing 
after the submerged cultivation is easier 
as compared with SSF. However, 
submerged cultivation induces high 
energy cost required for agitation, 
oxygen supply, stabilization of the 
temperature of the medium. This method 
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has significant industrial potential also 
due to the possibility of the process 
upscalling and operation of the large 
scale bioreactors.  
The choice of the technique for the 
submerged cultivation of higher fungi 
mycelial cultures depends on the desired 
effect (the product), and on the fungi 
physiological and morphological 
peculiarities.
 
Strategies for submerged cultivation of mycelial cultures 
The most frequently used technique 
for the submerged mushroom cultivation 
is batch culture. In the batch cultures no 
fresh nutrients are introduced into a 
substrate and no end products of 
metabolism are discharged during the 
process. Shake flask cultures are the 
simplest form of this technique. They are 
commonly used in cultivation of the 
inoculum prepared for inoculation of the 
bioreactor culture, and in experiments on 
the optimization of the culture medium 
(Asatiani et al. 2007, Turło et al. 2008, 
Malinowska et al. 2009a, Porras-
Arboleda et al. 2009, Lin 2010, Xu et al. 
2011, García et al. 2014, Homolka 2014). 
On a larger scale the mushroom cultures 
are grown in bioreactors of different 
construction, most commonly in air-lift 
type (stirred by the air stream) or in 
stirred-tank type (stirred with a 
mechanical stirrer) ones (Lee et al. 2004, 
Kim et al. 2007, Elisashvili et al. 2009, 
Turło et al. 2010a, b). In a fermenter it is 
possible to control the culture conditions, 
such as temperature, agitation, dissolved 
oxygen, temperature, substrate and 
metabolite concentrations and pH of the 
medium (Elisashvili 2012). Cultivation 
of higher fungi in the bioreactor 
submerged cultures is loaded, however, 
with greater difficulties than the cultures 
of single-celled organisms. In the 
submerged cultures morphological form 
of pellets is characteristic of higher fungi. 
The pellet size determines the oxygen 
and nutrient transport into its center. In 
the core region of a large pellet cells 
death resulting from lack of oxygen and 
nutrients occurs, therefore reduction of 
the pellet diameter is advantageous. 
Pellet size is influenced by different 
variables, such as agitation regime, 
density of the inoculum or sugar 
concentration in the medium (Petre et al. 
2010). According to our unpublished 
experiments, addition of polysorbate 
detergents (Tween) at a low 
concentration to a culture medium 
significantly reduces the diameter of 
pellets and does not inhibit growth of the 
strain (in L. edodes cultures). The 
mushroom mycelia and pellets are shear 
sensitive, therefore in the air-lift 
bioreactor the mycelial growth is better 
than in stirred tanks, due to lower shear 
forces. The culture viscosity significantly 
increases during cultivation, additionally 
fungal mycelia wrap around impellers, 
spread into sampling and nutrient feed 
lines and cause blockages. These 
drawbacks limit the time of operation in 
bioreactors.  
The other strategy used for mushroom 
submerged culture is fed-batch 
cultivation. The fed-batch cultures are 
carried out with a batch or continuous 
dispensing of sterile medium to the 
fermenter, which results in reducing the 
inhibitory effect of metabolic products of 
microbial growth and increased biomass 
growth (Shih et al. 2008). In repeated-fed 
batch fermentation process, in turn, 
periodically a portion of broth with 
accumulated mushroom biomass is taken 
from the fermenter and supplemented 
with fresh medium, while maintaining its 
constant volume. 
FOLIA BIOLOGICA ET OECOLOGICA 
 
 
BIOTECHNOLOGY OF HIGHER FUNGI   57 
 
Successful commercial implementation 
of the submerged cultivation of the 
mushrooms to the technical scale 
involves, irrespective of the purpose, the 
development of three phases:  
- inoculum preparation techniques 
and their improvements,  
- clear technical protocols for the 
final design and associated engineering 
processes,  
- protocols for monitoring, 
adjustment, continuity and maintenance 
of the engineering system. 
                  
Optimization of the strains and biotechnological processes  
Currently, there are two known 
methods of enhancing the productivity of 
a strain used in the biotechnological 
processes: (i) modification of the strain 
itself, by the use of mutagenesis, fusion 
of protoplasts or DNA transformation 
methods or (ii) optimization of the 
process by finding the optimum 
composition of a cultivation medium and 
conditions. At present, in the cultures of 
higher fungi the latter method is 
predominantly used. However, there are 
described and patented several methods 
for genome manipulations in higher fungi 
e.g. Flammulina velutipes (Cho et al. 
2006), Pleurotus nebrodensis (Inzenga) 
Quél. (Lin et al. 2008), Pleurotus 
ostreatus (Irie et al. 2001), Lentinula 
edodes (Terashima et al. 2002, 
Terashima et al. 2006, Kwan et al. 2012, 
Au et al. 2013, Tang et al. 2013) and 
others (Zhang et al. 2002, Romaine 
2011). Particularly intensive studies 
concern edible mushrooms. Agaricus 
bisporus is one of the most intensively 
studied species. Despite more than 60 
years of scientific investigation, advances 
in the genetic enhancement of this 
mushroom species has been impeded by 
its difficult genetics (Summerbell et al. 
1989, Van Griensven 1991, Romaine 
2011). Modifications of the genetic 
characteristics of homobasidiomycetes 
such as Agaricus bisporus via treatment 
with donor DNA, fusions using 
protoplasts and via matings between 
strains are patented (Huizing et al. 1995, 
Mikosh et al. 2001). These methods may 
be used in order to improve commercial 
characteristics of edible mushrooms and 
to commercially produce enzymes and 
metabolites in modified strains The use 
of transgenic basidiomycetes as a 
recombinant expression system for the 
production of a mucosal vaccine was also 
described (Florack & Rouwendal 2007). 
The first description of long-distance 
movement of a fully functional protein in 
a mushroom was given by Woolston et 
al. (2011). In 2006 Agarigen Inc. was 
founded, a Penn State spin-off company 
dedicated to harnessing transgenic A. 
bisporus for the biosynthesis of 
commercialized proteins. The correct 
selection of medium composition 
(carbon, nitrogen, phosphorus  
and microelement sources and 
concentrations, growth promoters, 
precursors for biosynthesis, other special 
supplements) and parameters of 
mushroom cultivation (duration of the 
process, temperature, pH, agitation, air 
supply) is crucial for the optimal 
mycelial growth and metabolite 
production. The optimization is essential 
for the development of an industrial-scale 
process. It should be taken into account 
that the physical and chemical factors are 
interconnected and affect the efficacy of 
the process. One-variable at a-time 
method for optimizing the culture 
medium and physical culture parameters 
involves changing one independent 
parameter (physical or chemical) while 
keeping the others constant. This method 
allows to determine the optimal 
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parameter (e.g. carbon source) but does 
not provide information on interactions 
and correlations between parameters. 
This may be reached by statistical 
optimization techniques that permit si-
multaneous optimization of many factors, 
thereby obtaining much quantitative 
information by only a few experimental 
trials. For example response surface 
methodology (RSM) enables the 
evaluation of the effects of many factors 
and their ractions to response variables. 
There are numerous reports on the use of 
this method in the optimization of the 
culture medium for simultaneous optimal 
strain growth and biosynthesis  
of secondary metabolite or 
exopolysaccharide (Feng et al. 2010, Luo 
et al. 2009). Similar experiments were 
also successfully conducted in our 
Department (Malinowska et al. 2009b). 
Our experience has shown, however, that 
the statistical methods for planning the 
experiment are not always effective in 
practice. We observed that optimal 
compositions of the substrate calculated 
by two different methods: based on 
central composite rotatable designs 
(CCRD) and using neural network were 
significantly different, moreover, none of 




The significant part of 
biotechnological processes described in 
this work is still at the stage of 
preliminary experiments. However, a 
large number of processes using cultures 
of higher fungi for biosynthesis of 
biologically active preparations and 
nutrients or for degradation of 
environmental pollutants have been 
patented. Presently, only a few 
companies use submerged cultures for 
the production of the commercially 
available products. Practical application 
of the biotechnological processes using 
mycelial cultures depends not only on 
their unique production potential, but 
also on development of industrial 
technologies for large-scale cultivation of 
fungal cultures and downstream 
processing which will ensure commercial 
success. 
The fact is that biotechnology, as an 
applied science, needs for its 
development knowledge in many fields. 
Elucidation of the physiological and 
biochemical mechanisms regulating 
biosynthesis and secretion of biologically 
active substances will enable scientiststo 
design and to optimize new 
biotechnological processes. Gaining 
knowledge concerning molecular biology 
of fungi will help to use genetic 
engineering methods e.g. recombinant 
DNA techniques in higher fungi. The 
production potential and adaptability of 
fungal cultures is enormous. Search for 
new, previously undescribed fungal 
metabolites gives a chance to discover a 
number of highly interesting substances 
with potential use in medicine.
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Streszczenie 
Od początku istnienia biotechnologii, jako mniej lub bardziej formalnie uznawanej 
dziedziny nauki, dużym zainteresowaniem badaczy cieszyły się grzyby, jako 
organizmy stosowane w biosyntezie i biotransformacjach różnego rodzaju substancji. 
Początkowo zainteresowanie dotyczyło jednak głównie gatunków grzybów zaliczanych 
nieformalnie do tzw. grzybów niższych. W biotechnologii farmaceutycznej 
przedstawiciele tej grupy, przykładowo, rodzajów Penicillium, Cephalosporium, 
Aspergillus lub Fusidium, są od dawna stosowani w produkcji antybiotyków, witamin, 
enzymów lub kwasów organicznych (cytrynowego, itakonowego, fusarowego, 
glukonowego). Drożdże z kolei są stosowane w technikach rekombinowanego DNA 
(produkcja insuliny) jako biorca transformowanego DNA. W przypadku tzw. grzybów 
wyższych, niejednorodnej pod względem systematycznym grupy grzybów, które 
tworzą owocniki, przez długi czas jedynym stosowanym procesem biotechnologicznym 
(obejmującym namnożenie inokulum, przygotowanie i sterylizację podłoża, inokulację, 
oraz hodowlę szczepu w określonych warunkach) była intensywna uprawa w 
podłożach stałych, dotycząca gatunków grzybów jadalnych. 
Za pierwsze próby stosowania grzybów wyższych w innego typu procesach 
biotechnologicznych można uznać opublikowane w 1966 przez Gregory’ego wyniki 
poszukiwań substancji o działaniu przeciwnowotworowym w pohodowlanych 
pożywkach płynnych, stosowanych do fermentacji wgłębnej różnych gatunków 
grzybów z klasy Basidiomycetes. Współcześnie coraz większe zainteresowanie 
biotechnologów budzi prowadzona w podłożach płynnych, w bioreaktorach o różnej 
konstrukcji, hodowla wgłębna mycelium wielu gatunków grzybów wyższych, 
należących głównie do Basidiomycetes. Celem opracowania (optymalizacji) tego typu 
procesów jest: 
- izolacja z mycelium lub podłoża pohodowlanego substancji farmakologicznie 
czynnych (leków, witamin) biosyntezowanych przez grzyba; 
- uzyskanie biomasy o wysokiej zawartości substancji odżywczych, do 
wykorzystania jako żywności funkcjonalnej i do produkcji suplementów diety;  
- uzyskanie biomasy o wysokiej zawartości substancji biologicznie czynnych 
(głównie antyoksydantów), do wykorzystania w kosmetologii;  
- izolacja z hodowli biosyntezowanych przez grzyby enzymów (głównie 
oksydoreduktaz), stosowanych następnie w procesach biotransformacji lub 
bioremediacji; 
- wykorzystanie hodowanego mycelium w procesach bioremediacji (tzw. 
mykoremediacja). 
Najlepiej opracowane i najłatwiejsze do przeprowadzenia są procesy 
biotechnologiczne z wykorzystaniem wielu gatunków grzybów saprofitycznych, 
najczęściej tzw. grzybów białej zgnilizny. Wiele spośród nich należy do nieformalnej 
grupy grzybów leczniczych. Hodowle wgłębne grzybów mykoryzowych przedstawiają 
nieco więcej problemów przy optymalizacji podłoża hodowlanego, niemniej również są 
prowadzone. 
Powodów zainteresowania biotechnologicznymi metodami hodowli grzybów jest 
kilka: 
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- ogromną zaletą jest krótki czas hodowli czystych kultur mycelialnych w 
fermentorach, zarówno na podłożach płynnych, jak i stałych. W porównaniu z czasem 
hodowli owocników grzybów daje to znaczne skrócenie czasu uzyskiwania 
porównywalnej biomasy; 
- hodowle mycelialne w bioreaktorach mogą być prowadzone w wysoce 
powtarzalnych warunkach, co skutkuje stałym składem uzyskiwanej biomasy. Ułatwia 
to standaryzację np. preparatów leczniczych uzyskiwanych z grzybów; 
- optymalizacja składu podłoży hodowlanych i warunków fizyko-chemicznych 
hodowli wpływa na regulację metabolizmu hodowanej grzybni. W efekcie pozwala to 
na znaczne podwyższenie wydajności biosyntezy związków biologicznie czynnych (np. 
metabolitów wtórnych); 
- możliwa jest kontrola i zachowanie biochemicznej i genetycznej identyczności 
hodowanej w fermentorze grzybni. 
Istnieją też poważne trudności związane ze stosowaniem nowoczesnych metod 
biotechnologicznych w przypadku grzybów wyższych:  
- nie wszystkie gatunki grzybów wyższych mają zdolność efektywnego wzrostu w 
postaci kultur mycelialnych w bioreaktorze; 
- w przypadku niektórych gatunków grzybów istnieją znaczące różnice w składzie 
chemicznym owocników grzyba i mycelium hodowanego metodami 
biotechnologicznymi. Nie zawsze różnice te są korzystne w przypadku stosowania 
hodowli mycelialnych do otrzymywania farmakologicznie czynnych związków; 
- szlaki metaboliczne biosyntezy wielu biologicznie czynnych substancji przez 
grzyby wyższe są ciągle jeszcze – w porównaniu z roślinami, lub grzybami 
strzępkowymi – słabo poznane i opisane. Znacząco utrudnia to projektowanie i 
optymalizację warunków procesu biotechnologicznego, dobór prekursorów biosyntezy 
lub promotorów wzrostu szczepu;  
- utrudnione jest stosowanie metod inżynierii genetycznej na skutek braku pełnej 
wiedzy o genach biosyntezy całego szlaku lub jego części.  
Niemniej pomimo trudności, producenci substancji leczniczych pochodzenia 
grzybowego (Lentinan, LEM, Grifon-D, PSK, PSP), suplementów diety oraz enzymów 
grzybowych, wprowadzają metody biotechnologiczne do produkcji. Zgodnie ze 
stosowanym od dawna w biotechnologii przemysłowej (np. przez producentów 
antybiotyków) zwyczajem, warunki procesu rzadko są opisywane w publikacjach, a 
czasami nie są nawet patentowane – co ułatwia zachowanie ich w tajemnicy. W latach 
90-tych XX wieku pojawiły się pierwsze informacje o możliwości stosowania metod 
rekombinowanego DNA dla grzybów wyższych. Współcześnie, liczne publikacje 
donoszą o opracowaniu metod transformacji oraz o uzyskaniu modyfikowanych 
genetycznie grzybów jadalnych. 
 
